A unique flagship institute at the University of Oxford combining insights into organ development and regeneration to treat birth defects and acquired disease

Meet François Halloy, SNSF Postdoctoral Research Fellow in the Wood Group, whose research focuses on the development of oligonucleotide therapeutics for the treatment of neuromuscular disorders. Although oligonucleotide drugs are powerful tools for treating genetic disorders, they suffer from several limitations related to their chemical structure and limited accumulation into important organs. Among those are brain, spinal cord, heart and skeletal muscle – all important tissues to target in the context of neuromuscular disease.